THE AUTHORS RESPOND.
作者信息
Xu Xiao, Katial Rohit, Schaefer Caroline, Szende Agota, Genofre Eduardo, Chung Yen
机构信息
BioPharmaceuticals Market Access and Pricing, AstraZeneca, Gaithersburg, MD; BioPharmaceuticals Global Medical Affairs, AstraZeneca, Gaithersburg, MD.
BioPharmaceuticals Global MedicalAffairs, AstraZeneca, Gaithersburg, MD.
出版信息
J Manag Care Spec Pharm. 2024 Apr;30(4):398-399. doi: 10.18553/jmcp.2024.30.4.398.
Abstract
摘要
相似文献
1
THE AUTHORS RESPOND.
J Manag Care Spec Pharm. 2024 Apr;30(4):398-399. doi: 10.18553/jmcp.2024.30.4.398.
2
Disaster management among pediatric surgeons: preparedness, training and involvement.
Am J Disaster Med. 2008 Jan-Feb;3(1):5-14.
3
Training healthcare providers to respond to intimate partner violence against women.
Cochrane Database Syst Rev. 2021 May 31;5(5):CD012423. doi: 10.1002/14651858.CD012423.pub2.
4
Transcriptomic analysis of treated by a potential phytonematicide, punicalagin.
J Nematol. 2020;52:1-14. doi: 10.21307/jofnem-2020-001.
5
Questions and Quandaries: How to respond to reviewer comments.
Adv Health Sci Educ Theory Pract. 2023 Mar;28(1):7-12. doi: 10.1007/s10459-023-10213-2. Epub 2023 Feb 28.
6
Reprint requests for family medicine literature: how do we respond?
Fam Med. 1990 Sep-Oct;22(5):404-5.
7
The Authors Respond.
J Manag Care Spec Pharm. 2020 Mar;26(3):335-336. doi: 10.18553/jmcp.2020.26.3.335.
8
Cumulative advantage and citation performance of repeat authors in scholarly journals.
PLoS One. 2022 Apr 13;17(4):e0265831. doi: 10.1371/journal.pone.0265831. eCollection 2022.
9
Methods for obtaining unpublished data.
Cochrane Database Syst Rev. 2011 Nov 9;2011(11):MR000027. doi: 10.1002/14651858.MR000027.pub2.
10
Survey of conflict-of-interest disclosure policies of ophthalmology journals.
Ophthalmology. 2009 Jun;116(6):1093-6. doi: 10.1016/j.ophtha.2008.12.053. Epub 2009 Apr 19.
本文引用的文献
1
A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
J Manag Care Spec Pharm. 2023 Nov;29(11):1193-1204. doi: 10.18553/jmcp.2023.23034. Epub 2023 Oct 5.
2
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
J Allergy Clin Immunol. 2022 Nov;150(5):1097-1105.e12. doi: 10.1016/j.jaci.2022.05.024. Epub 2022 Jun 27.
3
REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma.
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2646-2656. doi: 10.1016/j.jaip.2022.05.042. Epub 2022 Jun 24.
4
Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study.
Ann Allergy Asthma Immunol. 2022 Jun;128(6):669-676.e6. doi: 10.1016/j.anai.2022.02.017. Epub 2022 Mar 2.
5
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
Lancet Respir Med. 2022 Jan;10(1):47-58. doi: 10.1016/S2213-2600(21)00352-0. Epub 2021 Oct 4.
6
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.
J Asthma Allergy. 2020 Jan 29;13:77-87. doi: 10.2147/JAA.S236609. eCollection 2020.
7
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.
Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12.
Zotero 插件